ScreenerHero

HALO Halozyme Therapeutics, Inc. - Common Stock

NAS · US · Healthcare · Biotechnology · halozyme.com
108.69USD-1.06%Mkt Cap: 12.47B $P/E: 32.22

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap12.47B USD
Enterprise Value14.42B USD
Revenue (TTM)1.66B USD
Gross Profit1.27B USD
Net Income (TTM)316.89M USD
Revenue/Share14.15 USD
Last Price108.69 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees423
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)32.22
P/E (Forward)10.57
PEG—
EV/EBITDA13.72
EV/Revenue8.67
P/S7.49
P/B87.26
EPS (TTM)3.42
EPS (Forward)10.39
52W Range
61.2385% of range116.85
52W High116.85 USD
52W Low61.23 USD
Profitability
Gross Margin76.27%
Oper. Margin59.80%
EBITDA Margin63.15%
Profit Margin22.69%
ROE649.18%
ROA12.55%
Growth
Revenue Growth47.70%
Earnings Growth42.90%
Cash Flow & Leverage
Operating CF651.56M USD
CapEx (TTM)294.74M USD
FCF Margin20.27%
FCF Yield2.71%
Net Debt1.95B USD
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity43.89
Current Ratio2.71
Quick Ratio1.99
Book Value/Sh1.26 USD
Cash/Share2.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)99.56 USD
Upside (mean)-8.4%
Target Range70.00 USD – 115.00 USD
70.00-8.4% to mean115.00
# Analysts9
Ownership
Shares Out.113.50M
Float112.19M
Insiders1.11%
Institutions111.95%
Short Interest
Short Ratio9.8d
Short % Float17.50%
Short % Out.13.35%
Shares Short15.15M
Short (prev mo.)14.64M
Technical
SMA 50102.93 (+5.6%)
SMA 20078.33 (+38.8%)
Beta0.88
S&P 52W Chg14.58%
Avg Vol (30d)2.34M
Avg Vol (10d)2.84M
Technical Indicators
RSI (14)55.3
MACD2.9936
MACD Signal4.1882
MACD Hist.-1.1946
BB Upper115.75 USD
BB Middle110.46 USD
BB Lower105.17 USD
BB Width9.58%
ATR (14)3.154 USD
Vol Ratio (20d)1.05x